Drug Discovery

Eisai and Biogen Announce Approval of LEQEMBI® (Lecanemab) for Alzheimer’s Disease Treatment in Hong Kong

LEQEMBI is now available for patients with mild cognitive impairment (MCI) or mild dementia, collectively referred to as early AD, the population in which ...

 July 11, 2024 | News

DP Technology Nominates DPT0416 as Preclinical Candidate for Alzheimer’s Disease Treatment

DP Technology, an "AI for Science" paradigm-driven company,  announced the nomination of DPT0416, a novel CNS penetrable small molecule targeting Lp-P...

 July 10, 2024 | News

A*STAR and SingHealth Collaborate on SGD$18 Million TISHUMAP Project to Transform Drug Discovery in Asia

A*STAR’s Genome Institute of Singapore (GIS) has secured nearly SGD$18 million to develop an innovative data platform, TISHUMAP1. This platform is se...

 July 09, 2024 | News

XPOVIO® Secures NMPA Approval for Treatment of R/R DLBCL in China, Expanding Its Indications

- Following its initial approval for the treatment of relapsed/refractory multiple myeloma (R/R MM), XPOVIO® has now received approval as a monoth...

 July 08, 2024 | News

South Korea's Genexine Merges with EPD Biotherapeutics to Enhance PROTAC Technology and Drug Pipeline

Genexine  a publicly-listed, clinical-stage Korean biopharmaceutical company committed to the discovery and development of novel biologics for the tre...

 July 05, 2024 | News

Eleva's Factor H Receives Orphan Drug Designation from European Commission for Treating C3 Glomerulopathy

 Eleva, a pioneer in unlocking difficult-to-produce biologics based on a breakthrough manufacturing platform, announced today that the European Commis...

 July 04, 2024 | News

South Korea's PharmAbcine Advances Novel nAMD Treatment PMC-403 to Key Phase 1 Milestones

PharmAbcine, a clinical-stage public company developing next generation therapeutics to treat medical unmet needs, announced today the decision to advance ...

 July 02, 2024 | News

European Commission Approves OBGEMSA™ (Vibegron) for Overactive Bladder Treatment by Pierre Fabre Laboratories

The European Commission (EC) has authorized the marketing of OBGEMSA™ (vibegron) by Pierre Fabre Laboratories for the symptomatic treatment of overac...

 July 01, 2024 | News

Cytiva Introduces Supor Prime Filters to Enhance High-Concentration Biologic Drug Manufacturing

Global life sciences leader Cytiva is addressing the distinct filtration needs of customers manufacturing high-concentration biologic drugs with its Supor ...

 June 28, 2024 | News

South Korea Approves Reimbursement for Antengene's XPOVIO®, Expanding Access to Relapsed/Refractory Multiple Myeloma Treatment

- XPOVIO® is the first XPO1 inhibitor approved for reimbursement by South Korea's National Health Insurance Service (NHIS) for the treat...

 June 27, 2024 | News

Simcere Zaiming's Enlituo® Receives NMPA Approval for mCRC Treatment

Simcere Zaiming, an innovative oncology company and a subsidiary of Simcere Pharmaceutical Group (2096.HK), announced that Enlituo® (generic name: cetu...

 June 27, 2024 | News

EU Approves HUTCHMED's FRUZAQLA® for Previously Treated Metastatic Colorectal Cancer

— Approval for previously treated metastatic colorectal cancer based on results from positive, global, Phase III FRESCO-2 Trial — — FRUZ...

 June 24, 2024 | News

Menarini Expands Partnership with Pharmacosmos to Bring Innovative Iron Deficiency Treatment to Singapore and Malaysia

Menarini Asia-Pacific (Menarini)  announced that it has expanded its partnership with Pharmacosmos A/S (Pharmacosmos), to include exclusive rights to ...

 June 19, 2024 | News

Ascentage Pharma Secures $1.3 Billion Deal with Takeda for Global Rights to Olverembatinib

Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas. ...

 June 17, 2024 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close